Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Symptoms of ovarian cancer.

Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S.

Obstet Gynecol. 2001 Aug;98(2):212-7.

PMID:
11506835
2.

Symptoms of ovarian cancer in young patients 2 years before diagnosis, a case-control study.

Behtash N, Ghayouri Azar E, Fakhrejahani F.

Eur J Cancer Care (Engl). 2008 Sep;17(5):483-7. doi: 10.1111/j.1365-2354.2007.00890.x. Epub 2008 Jun 2.

PMID:
18537813
3.

Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM.

Gynecol Oncol. 2003 Jul;90(1):75-82.

PMID:
12821345
4.

Early symptoms of ovarian cancer: a case-control study without recall bias.

Friedman GD, Skilling JS, Udaltsova NV, Smith LH.

Fam Pract. 2005 Oct;22(5):548-53. Epub 2005 Jun 17.

PMID:
15964871
5.

Development of an ovarian cancer symptom index: possibilities for earlier detection.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR.

Cancer. 2007 Jan 15;109(2):221-7.

6.

Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer.

Webb PM, Purdie DM, Grover S, Jordan S, Dick ML, Green AC.

Gynecol Oncol. 2004 Jan;92(1):232-9.

PMID:
14751164
7.

Ovarian cancer: can we make the clinical diagnosis earlier?

Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS.

Cancer. 2005 Oct 1;104(7):1398-407.

8.

Symptoms, coping strategies, and timing of presentations in patients with newly diagnosed ovarian cancer.

Chan YM, Ng TY, Lee PW, Ngan HY, Wong LC.

Gynecol Oncol. 2003 Sep;90(3):651-6.

PMID:
13678740
9.

Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer.

Ryerson AB, Eheman C, Burton J, McCall N, Blackman D, Subramanian S, Richardson LC.

Obstet Gynecol. 2007 May;109(5):1053-61.

PMID:
17470582
10.

Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumors.

Olsen CM, Cnossen J, Green AC, Webb PM.

Eur J Gynaecol Oncol. 2007;28(5):376-80.

PMID:
17966216
11.

Women's awareness of ovarian cancer risks and symptoms.

Lockwood-Rayermann S, Donovan HS, Rambo D, Kuo CW.

Am J Nurs. 2009 Sep;109(9):36-45; quiz 46. doi: 10.1097/01.NAJ.0000360309.08701.73.

PMID:
19704232
12.

Ovarian cancer: early symptom patterns.

Koldjeski D, Kirkpatrick MK, Swanson M, Everett L, Brown S.

Oncol Nurs Forum. 2003 Nov-Dec;30(6):927-33.

PMID:
14603350
13.

Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area.

Holly EA, Chaliha I, Bracci PM, Gautam M.

Clin Gastroenterol Hepatol. 2004 Jun;2(6):510-7.

PMID:
15181621
14.

Differences in symptoms between patients with benign and malignant ovarian neoplasms.

Attanucci CA, Ball HG, Zweizig SL, Chen AH.

Am J Obstet Gynecol. 2004 May;190(5):1435-7.

PMID:
15167861
15.

Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.

Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A.

Gynecol Oncol. 2001 Dec;83(3):466-71.

PMID:
11733956
16.

Aspirin and epithelial ovarian cancer.

Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE.

Prev Med. 2001 Dec;33(6):682-7.

PMID:
11716667
17.

Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer.

Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT.

Gynecol Oncol. 2004 Dec;95(3):672-9.

PMID:
15581980
18.

Prevalence and treatment of menopausal symptoms among breast cancer survivors.

Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA.

J Pain Symptom Manage. 2002 Jun;23(6):501-9.

PMID:
12067774
19.

Presenting symptoms of epithelial ovarian cancer.

Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF.

Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4.

PMID:
15904446
20.

The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.

Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, Chenevix-Trench G.

Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1287-93.

Supplemental Content

Support Center